Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 10
Do GLP-1 drugs reduce fat graft survival?
A scoping review flags several mechanisms through which GLP-1 receptor agonists may reduce fat graft survival. No clinical data exist yet.
Ipamorelin 3x a day: what the evidence says
No human trial has tested a three-times-daily ipamorelin protocol. Here is where the idea comes from and what is missing from the evidence.
IWQOL-Lite-CT: trial vs real-world scores
Real-world adults with obesity score far worse on the IWQOL-Lite-CT than STEP 1 semaglutide trial participants. The instrument works, but baselines differ.
Microdosing tirzepatide: what we know
No trial has tested tirzepatide below 2.5 mg. A 2026 Obesity commentary examines the growing practice of KwikPen microdosing.
Oral semaglutide dropout rates in Japan
A Japanese database study found that high HbA1c and concurrent metformin use predicted early discontinuation of oral semaglutide at the 3 mg starting dose.
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
BPC-157 Grey Market Risks and Quality
BPC-157 is sold online with no regulatory oversight. What COA testing can and cannot tell you about identity, purity, and contamination.
PT-141 Grey Market Risks and Quality
Grey-market PT-141 vials lack the controls of FDA-approved Vyleesi. What COA testing reveals about identity, purity, and contamination.
Retatrutide grey market risks
Retatrutide is unapproved and ineligible for compounding. Grey-market vials carry identity, purity, and contamination risks.
Semaglutide Grey Market Risks and Quality
Counterfeit Ozempic, compounded semaglutide salt forms, and dosing errors: what regulators have found and what a COA cannot tell you.
Semax Grey Market Risks and Quality Testing
Semax is sold online with no regulatory oversight outside Russia. What COA testing reveals about identity, purity, and contamination.
Tesamorelin Grey Market Risks and Quality
Tesamorelin is FDA-approved only for HIV lipodystrophy. Grey-market vials sold for off-label use carry identity, purity, and contamination risks.